How Investors May Respond To Royalty Pharma (RPRX) Pelacarsen Trial Failure

• Royalty Pharma reported that Novartis’ Phase 3 HORIZON trial for pelacarsen in atherosclerotic cardiovascular disease did not meet its primary endpoint, limiting the potential royalty stream tied to this antisense therapy.
• The firm emphasized that its US$500 million Ionis funding deal was built around steady Spinraza royalties, so it still expects to recover its capital and earn a modest return. It also reaffirmed a 2030 portfolio receipts target of US$4.7 billion or more.
• We will now look at how Royalty Pharma’s protective, Spinraza-focused structure around pelacarsen reshapes the broader investment narrative.

Scan how Royalty Pharma’s risk sharing compares with other royalty and healthcare deals by reviewing the hand picked list of solid balance sheet and fundamentals (24 results).

Royalty Pharma Investment Narrative Recap

To own Royalty Pharma, you need to believe in a long runway for buying drug royalties and recycling those cash flows into new deals. The pelacarsen setback challenges one sliver of that story but does not change the near term focus on receipts from existing therapies such as Spinraza, Trikafta and other large contributors. The key short term swing factor remains the firm’s ability to source attractive new royalties in a more crowded market. The biggest current operational risk still sits in portfolio concentration and deal competition rather than this single failed HORIZON outcome.

The January 2023 funding agreement with Ionis is the clearest reference point for this HORIZON update. Royalty Pharma paid US$500 million for a mix of Spinraza and pelacarsen royalties, with US$350 million tied to Spinraza and US$150 million to pelacarsen. Management now expects the Spinraza cash flows alone to cover the investment and produce a modest gain, with total Spinraza royalties capped at US$550 million at a 1.1x multiple. That structure limits downside from the trial miss but keeps attention on how efficiently the business redeploys those receipts into future royalty opportunities.

That said, before leaning too heavily on that comfort, there is one structural pressure in the Royalty Pharma story that still tends to get overlooked by many investors who only glance at the headline numbers...

Read the full Royalty Pharma narrative to see the case behind these numbers.

Royalty Pharma's current analyst script points to revenues of US$4.3b and earnings of US$1.9b by 2029, based on an assumed 19.5% annual increase in revenue. That path would take earnings from US$812.0m today to US$1.9b, an uplift of about 2.3x on current levels.

Royalty Pharma's forecasts place fair value at $64.75 compared with the $63.96 share price, essentially in line with its current price.

Exploring Other Perspectives

For Royalty Pharma, the real swing factor in the alternate narrative is macro pressure on drug pricing. The most cautious analysts already modeled slower top line progress, with revenue of about US$4.0b and earnings near US$3.2b by 2029, and a low 10.6x P/E. Their view could easily shift again after the pelacarsen news, so treat this as one of several viewpoints to explore.

To see how other investors are framing Royalty Pharma’s upside and downside, review the 3 other fair value estimates for Royalty Pharma.

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis.

• A great starting point for your Royalty Pharma research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Royalty Pharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Royalty Pharma's overall financial health at a glance.

Looking For More Royalty Pharma Style Investment Ideas?

If the Royalty Pharma story has sharpened your thinking about cash flow visibility and balance sheet strength, use that same lens across the wider market with the Simply Wall St Screener.

• If you want potential value combined with quality fundamentals, scan the market using the 49 high quality undervalued stocks and see which businesses match that brief.
• If resilience and capital protection matter most to you, filter for companies with steadier profiles through the 83 resilient stocks with low risk scores.
• If you prefer to focus on underfollowed opportunities with solid numbers, broaden your watchlist with the 17 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com